Prothena Corporation PLC
NASDAQ:PRTA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
15.3
40.66
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PRTA stock under the Base Case scenario is 44.76 USD. Compared to the current market price of 16.1 USD, Prothena Corporation PLC is Undervalued by 64%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Prothena Corporation PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PRTA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Prothena Corporation PLC
Balance Sheet Decomposition
Prothena Corporation PLC
Current Assets | 586m |
Cash & Short-Term Investments | 564.1m |
Other Current Assets | 21.9m |
Non-Current Assets | 59.6m |
PP&E | 15.6m |
Other Non-Current Assets | 44m |
Current Liabilities | 46.7m |
Accounts Payable | 9.3m |
Accrued Liabilities | 27.9m |
Other Current Liabilities | 9.5m |
Non-Current Liabilities | 16.9m |
Other Non-Current Liabilities | 16.9m |
Earnings Waterfall
Prothena Corporation PLC
Revenue
|
217.3m
USD
|
Operating Expenses
|
-308.6m
USD
|
Operating Income
|
-91.4m
USD
|
Other Expenses
|
40.4m
USD
|
Net Income
|
-50.9m
USD
|
Free Cash Flow Analysis
Prothena Corporation PLC
USD | |
Free Cash Flow | USD |
The company ended 2023 with $621 million in cash, strengthening its financial stability. They are progressing with PRX012 in a phase I trial, aiming for a dose that would permit entry into a registration-enabling study. Birtamimab's AFFIRM AL trial remains pivotal, with FDA approval pending results that demonstrate a significant impact on all-cause mortality (p ≤ 0.1). Revenue growth for the next year is expected to be flat, as management focuses on strategic priorities rather than short-term revenue maximization, while operating margin is forecasted to improve slightly.
What is Earnings Call?
PRTA Profitability Score
Profitability Due Diligence
Prothena Corporation PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Prothena Corporation PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
PRTA Solvency Score
Solvency Due Diligence
Prothena Corporation PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Prothena Corporation PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRTA Price Targets Summary
Prothena Corporation PLC
According to Wall Street analysts, the average 1-year price target for PRTA is 62.37 USD with a low forecast of 24.24 USD and a high forecast of 98.7 USD.
Dividends
Current shareholder yield for PRTA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PRTA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
Contact
IPO
Employees
Officers
The intrinsic value of one PRTA stock under the Base Case scenario is 44.76 USD.
Compared to the current market price of 16.1 USD, Prothena Corporation PLC is Undervalued by 64%.